Intranasal drug developer Impel NeuroPharma has hired Lynn C. Gold as Senior VP of Regulatory Affairs, the company said. Gold was most recently VP of Scientific and Regulatory Affairs at Camargo Pharmaceutical Services and had previously served as VP of Research and Process Development at Sonus Pharmaceuticals.
Impel NeuroPharma CEO Jon Congleton commented, “We welcome Lynn to the team at such an exciting time for Impel, as we approach multiple clinical and regulatory milestones across our pipeline of four CNS products delivered via our novel, nasal POD device platform. Lynn’s broad expertise in regulatory affairs, coupled with her depth of knowledge in the 505(b)(2) pathway, from pre-IND to commercialization, will be a tremendous attribute for our Impel team.”
Gold said, “I am thrilled to be joining Impel in their mission to bring innovative solutions to people managing CNS disorders. The drug-device combination products we are exploring stand to improve current treatment options, and my hope is to leverage my experience to help navigate the path towards realizing the full potential of the Impel pipeline. ”
Impel recently announced plans for a Phase 3 study of its INP101 intranasal dihydroergotamine (DHE) for the treatment of acute migraine, and the company is also developing intranasal L-dopa for the treatment of Parkinson’s disease and intranasal insulin for the treatment of Alzheimer’s disease.
Read the Impel NeuroPharma press release.
